|
1
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vogelstein B and Kinzler KW: Cancer genes
and the pathways they control. Nat Med. 10:789–799. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Knudson AG: Two genetic hits (more or
less) to cancer. Nat Rev Cancer. 1:157–162. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu J, Lichtenberg T, Hoadley KA, Poisson
LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee
AV, et al: An integrated TCGA pan-cancer clinical data resource to
drive high-quality survival outcome analytics. Cell.
173:400–416.e11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cheung G, Sahai A, Billia M, Dasgupta P
and Khan MS: Recent advances in the diagnosis and treatment of
bladder cancer. BMC Med. 11:132013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hurst CD and Knowles MA: Bladder cancer:
Multi-omic profiling refines the molecular view. Nat Rev Clin
Oncol. 15:203–204. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular characterization of urothelial bladder
carcinoma. Nature. 507:315–322. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Robertson AG, Kim J, Al-Ahmadie H,
Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA,
Akbani R, et al: Comprehensive molecular characterization of
muscle-invasive bladder cancer. Cell. 171:540–556.e25. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gentles AJ, Newman AM, Liu CL, Bratman SV,
Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD, et al: The
prognostic landscape of genes and infiltrating immune cells across
human cancers. Nat Med. 21:938–945. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jia D, Liu Z, Deng N, Tan TZ, Huang RY,
Taylor-Harding B, Cheon DJ, Lawrenson K, Wiedemeyer WR, Walts AE,
et al: A COL11A1-correlated pan-cancer gene signature of activated
fibroblasts for the prioritization of therapeutic targets. Cancer
Lett. 382:203–214. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shin G, Kang TW, Yang S, Baek SJ, Jeong YS
and Kim SY: GENT: Gene expression database of normal and tumor
tissues. Cancer Inform. 10:149–157. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Barretina J, Caponigro G, Stransky N,
Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV,
Sonkin D, et al: The cancer cell line encyclopedia enables
predictive modelling of anticancer drug sensitivity. Nature.
483:603–607. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Taylor AB and MacKinnon DP: Four
applications of permutation methods to testing a single-mediator
model. Behav Res Methods. 44:806–844. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mjelle R, Hegre SA, Aas PA, Slupphaug G,
Drabløs F, Saetrom P and Krokan HE: Cell cycle regulation of human
DNA repair and chromatin remodeling genes. DNA Repair (Amst).
30:53–67. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Park JE, Yi H, Kim Y, Chang H and Kim VN:
Regulation of Poly(A) tail and translation during the somatic cell
cycle. Mol Cell. 62:462–471. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Simon R, Atefy R, Wagner U, Forster T,
Fijan A, Bruderer J, Wilber K, Mihatsch MJ, Gasser T and Sauter G:
HER-2 and TOP2A coamplification in urinary bladder cancer. Int J
Cancer. 107:764–772. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zuiverloon TCM, de Jong FC, Costello JC
and Theodorescu D: Systematic review: Characteristics and
preclinical uses of bladder cancer cell lines. Bladder Cancer.
4:169–183. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dinney CP, Fishbeck R, Singh RK, Eve B,
Pathak S, Brown N, Xie B, Fan D, Bucana CD, Fidler IJ, et al:
Isolation and characterization of metastatic variants from human
transitional cell carcinoma passaged by orthotopic implantation in
athymic nude mice. J Urol. 154:1532–1538. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Morales C and Losada A: Establishing and
dissolving cohesion during the vertebrate cell cycle. Curr Opin
Cell Biol. 52:51–57. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kaufman DS, Shipley WU and Feldman AS:
Bladder cancer. Lancet. 374:239–249. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Als AB, Dyrskjøt L, von der Maase H, Koed
K, Mansilla F, Toldbod HE, Jensen JL, Ulhøi BP, Sengeløv L, Jensen
KM and Orntoft TF: Emmprin and survivin predict response and
survival following cisplatin-containing chemotherapy in patients
with advanced bladder cancer. Clin Cancer Res. 13:4407–4414. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Apolo AB, Vogelzang NJ and Theodorescu D:
New and promising strategies in the management of bladder cancer.
Am Soc Clin Oncol Educ Book. Jun 1–2015.(Epub ahead of print). doi:
10.14694/EdBook_AM.2015.35.105. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dyrskjøt L, Zieger K, Real FX, Malats N,
Carrato A, Hurst C, Kotwal S, Knowles M, Malmström PU, de la Torre
M, et al: Gene expression signatures predict outcome in
non-muscle-invasive bladder carcinoma: A multicenter validation
study. Clin Cancer Res. 13:3545–3551. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS,
Jeong P, Kim MJ, Yun SJ, Lee KM, Moon SK, et al: Predictive value
of progression-related gene classifier in primary non-muscle
invasive bladder cancer. Mol Cancer. 9:32010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Blaveri E, Simko JP, Korkola JE, Brewer
JL, Baehner F, Mehta K, Devries S, Koppie T, Pejavar S, Carroll P
and Waldman FM: Bladder cancer outcome and subtype classification
by gene expression. Clin Cancer Res. 11:4044–4055. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dobbin ZC, Katre AA, Steg AD, Erickson BK,
Shah MM, Alvarez RD, Conner MG, Schneider D, Chen D and Landen CN:
Using heterogeneity of the patient-derived xenograft model to
identify the chemoresistant population in ovarian cancer.
Oncotarget. 5:8750–8764. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang E: Senescent human fibroblasts resist
programmed cell death, and failure to suppress bcl2 is involved.
Cancer Res. 55:2284–2292. 1995.PubMed/NCBI
|
|
30
|
Gal A, Sjöblom T, Fedorova L, Imreh S,
Beug H and Moustakas A: Sustained TGF beta exposure suppresses Smad
and non-Smad signalling in mammary epithelial cells, leading to EMT
and inhibition of growth arrest and apoptosis. Oncogene.
27:1218–1230. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cao QH, Liu F, Li CZ, Liu N, Shu M, Lin Y,
Ding L and Xue L: Testes-specific protease 50 (TSP50) promotes
invasion and metastasis by inducing EMT in gastric cancer. BMC
Cancer. 18:942018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stine ZE, Walton ZE, Altman BJ, Hsieh AL
and Dang CV: MYC, metabolism, and cancer. Cancer Discov.
5:1024–1039. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Järvinen TA and Liu ET: Topoisomerase
IIalpha gene (TOP2A) amplification and deletion in cancer-more
common than anticipated. Cytopathology. 14:309–313. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Aumayr K, Klatte T, Neudert B, Birner P,
Shariat S, Schmidinger M, Susani M and Haitel A: HER2 and TOP2A
gene amplification and protein expression in upper tract urothelial
carcinomas. Pathol Oncol Res. 24:575–581. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Al-Kuraya K, Novotny H, Bavi P, Siraj AK,
Uddin S, Ezzat A, Sanea NA, Al-Dayel F, Al-Mana H, Sheikh SS, et
al: HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in
colorectal cancer. J Clin Pathol. 60:768–772. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bofin AM, Ytterhus B and Hagmar BM: TOP2A
and HER-2 gene amplification in fine needle aspirates from breast
carcinomas. Cytopathology. 14:314–319. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fasching PA, Weihbrecht S, Haeberle L,
Gasparyan A, Villalobos IE, Ma Y, Ekici AB, Wachter DL, Hartmann A,
Beckmann MW, et al: HER2 and TOP2A amplification in a
hospital-based cohort of breast cancer patients: Associations with
patient and tumor characteristics. Breast Cancer Res Treat.
145:193–203. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Martín-Subero JI, Harder L, Gesk S, Schoch
R, Novo FJ, Grote W, Calasanz MJ, Schlegelberger B and Siebert R:
Amplification of ERBB2, RARA, and TOP2A genes in a myelodysplastic
syndrome transforming to acute myeloid leukemia. Cancer Genet
Cytogenet. 127:174–176. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Murphy AJ, Hughes CA, Barrett C, Magee H,
Loftus B, O'Leary JJ and Sheils O: Low-level TOP2A amplification in
prostate cancer is associated with HER2 duplication, androgen
resistance, and decreased survival. Cancer Res. 67:2893–2898. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Schaefer-Klein JL, Murphy SJ, Johnson SH,
Vasmatzis G and Kovtun IV: Topoisomerase 2 alpha cooperates with
androgen receptor to contribute to prostate cancer progression.
PLoS One. 10:e01423272015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Champoux JJ: DNA topoisomerases:
Structure, function, and mechanism. Annu Rev Biochem. 70:369–413.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Rhodes DR, Yu J, Shanker K, Deshpande N,
Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM:
Large-scale meta-analysis of cancer microarray data identifies
common transcriptional profiles of neoplastic transformation and
progression. Proc Natl Acad Sci USA. 101:9309–9314. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xia L, Wang M, Li H, Tang X, Chen F and
Cui J: The effect of aberrant expression and genetic polymorphisms
of Rad21 on cervical cancer biology. Cancer Med. May 24–2018.(Epub
ahead of print). doi: 10.1002/cam4.1592. View Article : Google Scholar
|
|
44
|
Ahn JH, Kim TJ, Lee JH and Choi JH: Mutant
p53 stimulates cell invasion through an interaction with Rad21 in
human ovarian cancer cells. Sci Rep. 7:90762017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yamamoto G, Irie T, Aida T, Nagoshi Y,
Tsuchiya R and Tachikawa T: Correlation of invasion and metastasis
of cancer cells, and expression of the RAD21 gene in oral squamous
cell carcinoma. Virchows Arch. 448:435–441. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tessitore A, Cicciarelli G, Del Vecchio F,
Gaggiano A, Verzella D, Fischietti M, Vecchiotti D, Capece D,
Zazzeroni F and Alesse E: MicroRNAs in the DNA damage/repair
network and cancer. Int J Genomics. 2014:8202482014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Deb S, Xu H, Tuynman J, George J, Yan Y,
Li J, Ward RL, Mortensen N, Hawkins NJ, McKay MJ, et al: RAD21
cohesin overexpression is a prognostic and predictive marker
exacerbating poor prognosis in KRAS mutant colorectal carcinomas.
Br J Cancer. 110:1606–1613. 2014. View Article : Google Scholar : PubMed/NCBI
|
